| Literature DB >> 31890014 |
Kristy Iskandar1,2, Andika Priamas Nugrahanto2, Nissya Ilma2, Alvin Santoso Kalim2, Guritno Adistyawan3, Roni Naning4.
Abstract
BACKGROUND: Duchenne Muscular Dystrophy (DMD) is a fatal X-linked recessive neuromuscular disease, characterized by progressive loss of muscle strength. Respiratory failure is the main cause of morbidity and mortality in DMD patients. Respiratory devices have been reported to increase the effectiveness of cough and pulmonary function, thus prolong the survival rate. However, there is scarcity of studies about DMD patients' respiratory profiles and usage of respiratory devices in Indonesia.Entities:
Keywords: Duchenne muscular dystrophy; Respiratory devices; Respiratory function
Year: 2019 PMID: 31890014 PMCID: PMC6912939 DOI: 10.1186/s12919-019-0179-4
Source DB: PubMed Journal: BMC Proc ISSN: 1753-6561
Patient characteristic
| Characteristic | n |
|---|---|
| Total number of patients | 8 |
| Age, y | 13.25 ± 3.96 |
| Weight, kg | 27.48 ± 5.50 |
| Height, cm | 148.99 ± 7.28 |
| BMI, kg/m2 | 12.46 ± 2.85 |
| Genetic | |
| Deletion | 6 (75%) |
| Duplication | 0 (0%) |
| Point mutation | 0 (0%) |
| Undefined mutation | 2 (25%) |
| Age of Initial Symptom, ya | 3.92 ± 2.27 |
| Age when Diagnosed, y | 5.12 ± 3.02 |
| Age at First Walk, y | 1.39 ± 0.35 |
| Scoliosis | |
| Mild (<20o) | 2 (25%) |
| Moderate (20o < x < 40o) | 3 (37.5%) |
| Severe (>40o) | 3 (37.5%) |
| Spinal Fusion | 0 (0%) |
| CK Level | 5056.88 ± 4243.63 |
| Family Historyb | |
| Yes | 6 (75%) |
| No | 2 (25%) |
| Steroid Treatment | |
| Yes | 5 (62.5%) |
| No | 1 (12.5%) |
| Paused | 2 (25%) |
| Immunizationc | |
| Yes | 0 (0%) |
| No | 8 (100%) |
aInitial symptom: first onset of motoric symptoms complained by the subject parents. Symptoms were included frequent falling, motoric regression, tiptoe walking, waddling gait or gower sign
bThree generation family member with the same symptom or diagnosed as genetic neuromuscular disease
cInfluenza and PCV Immunization
Pulmonary function
| Respiratory characteristic | Mean |
|---|---|
| FVC (L) | 1005 ± 446.51 |
| FVC (% pred) | 40.25 ± 20.91 |
| FEV1 (L) | 765.71 ± 432.31 |
| FEV1 (% pred) | 32.91 ± 22.54 |
| FEV1/FVC (%) | 82.42 ± 24.00 |
| Nocturnal Respiratory Status | |
| SpO2 | |
| Most common SpO2 (%) | 96.5 ± 1.19 |
| Lowest SpO2 (%) | 91.13 ± 5.33 |
| Duration of SpO2 < 90% (%) | 1.09 ± 1.85 |
| Duration of SpO2 < 90% (min) | 5 ± 8.87 |
| pCO2 | |
| Most common pCO2 (mmHg) | 31.13 ± 5.08 |
| Highest pCO2 (mmHg) | 36.5 ± 3.42 |
| pCO2 > 45 mmHg (%) | 0 |
| Awake Respiratory Status | 98.38 ± 1.19 |
| SpO2 (%) | 29.25 ± 4.86 |
| pCO2(mmHg) | 19.13 ± 1.88 |
| Respiration Rate (x/minutes) | |
PCF value
| PCF value (L/min) | Mean ± SD |
|---|---|
| Unassisted Cough | 160 ± 44.58 |
| Manually Assisted Exsufflation | 193 ± 46.72 |
| Assisted Air Stacking | 167.4 ± 46.72 |
| Combined Technique | 180 ± 45.69 |
Fig. 1Peak Cough Flow (PCF) value at baseline, after chest compression, after air stacking using ambu bag and after combined technique (chest compression and ambu bag air stacking), PCF < 160 L/min: 2 patients, PCF > 160 L/min: 3 patients. *p-value< 0.05.
Fig. 2Correlation between lung function (FVC and FEV1) and clinical characteristic (age and degree of cobbs angle)